Corpus ID: 54072275

INVOSSA TM – a cell and gene therapy for osteoarthritis

@inproceedings{Emanuel2018INVOSSAT,
  title={INVOSSA TM – a cell and gene therapy for osteoarthritis},
  author={K. Emanuel and K. Mader and M. Peeters and I. Kingma and C.M.E. Rustenburg and Pieter-Paul A. Vergroesen and Sammon and T. Smit},
  year={2018}
}
INTRODUCTION: Osteoarthritis (OA) is a debilitating and painful disease that is growing in incidence due to the aging population. Current treatment modalities attempt to address pain and improve function, but no treatment is curative. Until recently, OA was seen as the result of joint trauma, but is now recognized as a chronic, inflammatory process. OA’s inflammatory process is an imbalance between pro-inflammatory and anti-inflammatory cytokines. This process can be interrupted by TGF-β1… Expand

Figures and Tables from this paper

References

SHOWING 1-10 OF 24 REFERENCES
Tissue Eng Regen Med, 2017
  • 2017
ACKNOWLEDGEMENTS: This work was supported by the DFG Research network (FOR2407/1): ExCarBon SP7
  • Felka et al: Osteoarthritis Cartilage
  • 2009
pathways driving RUNX3 and MEF2C transcription factor levels in MPC may be promising for guiding MPC differentiation towards an articular chondrocyte phenotype
  • 2006
2013) that in vivo herniations result from anular failure (AF, 35%) or endplate junction failure (EPJF, 65%). Both cases have been reproduced in vitro
  • (Wilke et al
  • 2015
Manufacturing meets Biofabrication Part 2, 2016
  • Adv Funct Mat,
  • 2015
Arthritis & rheumatology
  • 2014
...
1
2
3
...